ROS1 and non-small cell lung carcinoma: Because the kinase domains of ALK and ROS1 share 77% homology at the protein sequence level and crizotinib is highly active for both ALK and ROS1 [115], clinical investigation into the treatment of NSCLC patients with ROS1 rearrangement has been pursued.